MTOR and neoplasm: So far, small molecules that indirectly affect FoxP3 upregulation or activation to turn off Tregs, for example, MEK inhibitors,17 PI3Kδ inhibitors,18,19 and the small molecule NLOC-015A that targets EGFR/MAP2K1/mTOR/YAP120 have been proven to boost anti-tumor immune responses in vitro but have not progressed to in vivo validation due to low selectivity versus Teffs.